Differentiated thyroid cancer: intermediate/high radioactive iodine dose shows benefit in low-risk patients

  • Albano D & al.
  • Endocrine
  • 29 Nov 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Intermediate/high radioactive iodine (RAI) dose is associated with improved successful ablation and excellent response rates compared with low dose in patients with low-risk differentiated thyroid cancer (DTC).

Why this matters

  • The management of patients with low-risk DTC is controversial, and some prior studies have shown equivalent outcomes between low- and high-dose RAI.

Key results

  • Patients who received intermediate-/high-dose RAI (1.85-3.7 GBq) had higher rates of successful ablation (67% vs 35%; P<.001 and excellent response vs p=".020)" compared with those who received low-dose rai gbq style="list-style-type:circle;">
  • More patients in the low-dose group had an indeterminate response (64% vs 43%; P=.005).
  • Both intermediate-/high- and low-dose groups had similar detection rates of nodal and distant metastases.
  • Study design

    • 277 patients with low-risk DTC who received total thyroidectomy and RAI (174 low dose; 103 intermediate-high dose) were analyzed for outcomes.
    • Funding: None disclosed.

    Limitations

    • Retrospective study.